153 related articles for article (PubMed ID: 3718544)
21. Dehydrogenase binding by tiazofurin anabolites.
Goldstein BM; Bell JE; Marquez VE
J Med Chem; 1990 Apr; 33(4):1123-7. PubMed ID: 1969483
[TBL] [Abstract][Full Text] [Related]
22. Targets and markers of selective action of tiazofurin.
Weber G; Natsumeda Y; Pillwein K
Adv Enzyme Regul; 1985; 24():45-65. PubMed ID: 2424286
[TBL] [Abstract][Full Text] [Related]
23. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.
Gharehbaghi K; Sreenath A; Hao Z; Paull KD; Szekeres T; Cooney DA; Krohn K; Jayaram HN
Biochem Pharmacol; 1994 Oct; 48(7):1413-9. PubMed ID: 7945441
[TBL] [Abstract][Full Text] [Related]
24. Synergistic action of tiazofurin and genistein on growth inhibition and differentiation of K-562 human leukemic cells.
Li W; Weber G
Life Sci; 1998; 63(22):1975-81. PubMed ID: 9839541
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxicity of tiazofurin and its arabinose and xylose analogues in K562 cells.
Zhen W; Jayaram HN; Marquez VE; Goldstein BM; Cooney DA; Weber G
Biochem Biophys Res Commun; 1991 Oct; 180(2):933-8. PubMed ID: 1683233
[TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacology of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Green RM; Stewart DJ; Maroun JA
Invest New Drugs; 1986; 4(4):387-94. PubMed ID: 3583646
[TBL] [Abstract][Full Text] [Related]
27. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
Lui MS; Faderan MA; Liepnieks JJ; Natsumeda Y; Olah E; Jayaram HN; Weber G
J Biol Chem; 1984 Apr; 259(8):5078-82. PubMed ID: 6143752
[TBL] [Abstract][Full Text] [Related]
28. Induction of HL60 cell differentiation by tiazofurin and its analogues: characterization and efficacy.
Goldstein BM; Leary JF; Farley BA; Marquez VE; Levy PC; Rowley PT
Blood; 1991 Aug; 78(3):593-8. PubMed ID: 1650262
[TBL] [Abstract][Full Text] [Related]
29. Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells.
Olah E; Natsumeda Y; Ikegami T; Kote Z; Horanyi M; Szelenyi J; Paulik E; Kremmer T; Hollan SR; Sugar J
Proc Natl Acad Sci U S A; 1988 Sep; 85(17):6533-7. PubMed ID: 2901100
[TBL] [Abstract][Full Text] [Related]
30. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
Sokoloski JA; Sartorelli AC
Mol Pharmacol; 1985 Dec; 28(6):567-73. PubMed ID: 2867464
[TBL] [Abstract][Full Text] [Related]
31. Tiazofurin metabolism in human lymphoblastoid cells: evidence for phosphorylation by adenosine kinase and 5'-nucleotidase.
Fridland A; Connelly MC; Robbins TJ
Cancer Res; 1986 Feb; 46(2):532-7. PubMed ID: 3000575
[TBL] [Abstract][Full Text] [Related]
32. Unique bioactivation of tiazofurin--studies with resistant cells.
Kuttan R
Indian J Biochem Biophys; 1989 Jun; 26(3):160-5. PubMed ID: 2620910
[TBL] [Abstract][Full Text] [Related]
33. Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion.
Jayaram HN; Lapis E; Tricot G; Kneebone P; Paulik E; Zhen W; Engeler GP; Hoffman R; Weber G
Int J Cancer; 1992 May; 51(2):182-8. PubMed ID: 1568787
[TBL] [Abstract][Full Text] [Related]
34. Critical issues in chemotherapy with tiazofurin.
Weber G
Adv Enzyme Regul; 1989; 29():75-95. PubMed ID: 2699155
[TBL] [Abstract][Full Text] [Related]
35. The disposition and metabolism of tiazofurin in rodents, rabbits, and dogs.
Arnold ST; Jayaram HN; Harper GR; Litterst CL; Malspeis L; DeSouza JJ; Staubus AE; Ahluwalia GS; Wilson YA; Cooney DA
Drug Metab Dispos; 1984; 12(2):165-73. PubMed ID: 6144481
[TBL] [Abstract][Full Text] [Related]
36. Involvement of guanine nucleotides in superoxide release by fluoride-treated neutrophils. Implications for a role of a guanine nucleotide regulatory protein.
English D; Rizzo MT; Tricot G; Hoffman R
J Immunol; 1989 Sep; 143(5):1685-91. PubMed ID: 2547872
[TBL] [Abstract][Full Text] [Related]
37. Phase I clinical study with pharmacokinetic analysis of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193) administered as a five-day infusion.
Trump DL; Tutsch KD; Koeller JM; Tormey DC
Cancer Res; 1985 Jun; 45(6):2853-8. PubMed ID: 3986812
[TBL] [Abstract][Full Text] [Related]
38. Schedule-dependent synergistic action of tiazofurin and dipyridamole on hepatoma 3924A cells.
Jayaram HN; Murayama K; Pillwein K; Zhen W; Weber G
Cancer Chemother Pharmacol; 1992; 31(2):93-6. PubMed ID: 1451238
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of tiazofurin in dogs.
Obeng EK; Vallner JJ; Cadwallader DE; Tackett RL
Biopharm Drug Dispos; 1987; 8(2):125-32. PubMed ID: 3593893
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of resistance to 6-aminonicotinamide.
Saunders PP; Muhs MA; Arimilli S
Anticancer Res; 1996; 16(2):843-8. PubMed ID: 8687139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
